WO2024110558A1 - Adapter for filling and subsequent closing of a pharmaceutical composition container, and container with adapter - Google Patents
Adapter for filling and subsequent closing of a pharmaceutical composition container, and container with adapter Download PDFInfo
- Publication number
- WO2024110558A1 WO2024110558A1 PCT/EP2023/082757 EP2023082757W WO2024110558A1 WO 2024110558 A1 WO2024110558 A1 WO 2024110558A1 EP 2023082757 W EP2023082757 W EP 2023082757W WO 2024110558 A1 WO2024110558 A1 WO 2024110558A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adapter
- container
- housing
- cavity
- axis
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 238000004891 communication Methods 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims description 89
- 230000013011 mating Effects 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 description 41
- 230000004069 differentiation Effects 0.000 description 24
- -1 polypropylene Polymers 0.000 description 7
- 229960002964 adalimumab Drugs 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920002725 thermoplastic elastomer Polymers 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 102100026445 A-kinase anchor protein 17A Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108700002054 Glucocorticoid-Induced TNFR-Related Proteins 0.000 description 2
- 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 2
- 102000007346 Hepatitis A Virus Cellular Receptor 2 Human genes 0.000 description 2
- 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 2
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 2
- 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108010004351 growth arrest-specific protein 6 Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-phenyl-1h-indole-6-carboxylic acid Chemical compound C=1C=CC=CC=1C=1N(CC(=O)N2CCOCC2)C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150066398 CXCR4 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102000012085 Endoglin Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101000653548 Homo sapiens Trichoplein keratin filament-binding protein Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100030645 Trichoplein keratin filament-binding protein Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- FUKOGSUFTZDYOI-BMANNDLBSA-O beacopp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 description 1
- 229940126166 belantamab mafodotin-blmf Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- AFTOJIAPXHGBGH-UHFFFAOYSA-N bis(2-oxopyridin-1-yl) carbonate Chemical compound C1=CC=CC(=O)N1OC(=O)ON1C=CC=CC1=O AFTOJIAPXHGBGH-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229950006925 emicizumab Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950001616 erenumab Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- CNZOFNMWZBNPLL-OSKRVHINSA-L flot regimen Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)C(O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 CNZOFNMWZBNPLL-OSKRVHINSA-L 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229950000118 galcanezumab Drugs 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940076155 protein modulator Drugs 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229950007085 ravulizumab Drugs 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 229950000143 sacituzumab govitecan Drugs 0.000 description 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229940060041 satralizumab Drugs 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940121503 tafasitamab Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- YCCHNFGPIFYNTF-UHFFFAOYSA-N tertiary cymene hydroperoxide Natural products CC1=CC=C(C(C)(C)OO)C=C1 YCCHNFGPIFYNTF-UHFFFAOYSA-N 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
- B65B3/045—Methods of, or means for, filling the material into the containers or receptacles for filling flexible containers having a filling and dispensing spout, e.g. containers of the "bag-in-box"-type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
- B65B3/10—Methods of, or means for, filling the material into the containers or receptacles by application of pressure to material
- B65B3/12—Methods of, or means for, filling the material into the containers or receptacles by application of pressure to material mechanically, e.g. by pistons or pumps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B39/00—Nozzles, funnels or guides for introducing articles or materials into containers or wrappers
- B65B39/06—Nozzles, funnels or guides for introducing articles or materials into containers or wrappers adapted to support containers or wrappers
- B65B39/08—Nozzles, funnels or guides for introducing articles or materials into containers or wrappers adapted to support containers or wrappers by means of clamps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
- B65B55/02—Sterilising, e.g. of complete packages
- B65B55/027—Packaging in aseptic chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B67/00—Apparatus or devices facilitating manual packaging operations; Sack holders
- B65B67/02—Packaging of articles or materials in containers
- B65B67/04—Devices facilitating the insertion of articles or materials into bags, e.g. guides or chutes
Definitions
- the present disclosure relates to the filling of a drug container.
- the disclosure is particularly, but not exclusively, applicable to an adapter for filling and subsequently closing a pharmaceutical composition container, such as a flat medicament bag made of plastics.
- An exemplary drug container is a flat medicament bag made of one or more plastics showing excellent barrier properties that may allow long storage like glass vials.
- Such an exemplary drug container may contain three main parts: a film of one or more layers, which is welded to form a bag; a port, which contains interfaces and provides access to the interior of the bag; and a closure to close the port.
- US 8 763 798 B2 relates to a closure for filling and sealing receptacles containing medicinal fluids, a method for filling a receptacle with a medicinal fluid and sealing the receptacle.
- the closure used in the method comprises a mounting piece that may be attached to the receptacle and a connector piece that may be connected to a connector piece of a filling device.
- a closure body is arranged between the mounting piece and the connector piece, in which a closure piece for sealing the closure sits.
- the closure piece may be slid between a position sealing the closure and a position which opens the closure.
- the closure is sealed tight with a removable protective cap.
- the receptacle is filled through the closure in a clean room. After filling, the closure is sealed by pressing the closure piece into the closure.
- Such drug containers have generally been developed to be filled in industrial environment on an automated filling station in aseptic environment, in order to minimize the risk of contamination. However, this can be inconvenient and involve undesirable logistics.
- An object of the invention is to provide a filling tool that allows for the filling of a drug container and to provide a medicament bag designed for being filled in either an industrial environment or in a clinical setting, such as a treatment room or pharmacy, by a medical practitioner, nurse or pharmacist.
- This object is achieved with an adapter according to independent claim 1, a container with an adapter according to independent claim 11 or 12, or a combination according to claim 15.
- Preferred embodiments are defined in the dependent claims.
- an adapter for filling and subsequent closing of a pharmaceutical composition container comprising: a housing having a first axis, the housing having a cavity with a cavity opening coupleable to a port of the container; a closure element arranged in the cavity and displaceable from a first position to a second position, in a direction along the first axis; a push rod being arranged at least partially outside the cavity and being movable by a user in a direction along the first axis for displacing the closure element; the housing having an entry port with an entry port opening in communication with the cavity, at least part of the entry port opening being located axially between the first position of the closure element and the cavity opening when viewed along the first axis.
- the entry port has an entry port channel, at least part of the length of which is perpendicular to or is inclined with respect to the first axis.
- the adaptor has two opposing sides along the first axis, one side being the side where the adapter is connectable to a port of the container, the other, second side for being held and/or operated by a user.
- the push rod has a generally T-shape in cross-section along the first axis.
- the adapter further comprises a pierceable septum in the entry port channel.
- the entry port comprises one or more of a self-sealing elastomeric septum, needleless connector, female Luer connection, male Luer connection, Luer access valve, Luer activated device, or combinations thereof, at the end opposite to the cavity opening.
- the entry port is configured to cooperate with at least one or more of a male Luer connector, female Luer connector, vial adapter, vial spike, IV tubing set spike, or combinations thereof.
- the entry port is configured to cooperate with at least one closed-system transfer device or component.
- the closure element is adapted to seal the port of the container.
- the closure element is configured to remove substantially all of a drug from the cavity.
- the closure element is configured to remove substantially all of a drug from the cavity after filling and displacement of the closure element.
- the closure element is adapted to enter into a connection with the port of the container and to be released from the adapter upon removal of the adapter from the container.
- the closure element is a plunger for expelling fluid from the cavity.
- the closure element is a substantially elastomeric material.
- the closure element is a blend of thermoplastic elastomer and an olefin polymer.
- the cavity is made from an olefin polymer.
- the adapter is configured such that one or more portions of the adapter or the housing are removed from the container after filling.
- the adapter is configured such that one or more portions of the adapter or the housing are removed from the container after filling and displacement of the closure element.
- the adapter housing has a protruding structure for being gripped by a user during use.
- the adapter housing may be generally elongate along the direction of the first axis, preferably generally cylindrical.
- the push rod protrudes along the first axis from the adapter housing (510) at the side for being held and/or operated by a user.
- the push rod protrudes along the first axis from the adapter housing at the side for being held and/or operated by a user.
- the adapter housing has one or more connecting elements for connecting the adapter housing with the container housing.
- the one or more connecting elements may provide a releasable connection between the adapter housing with the container housing.
- the releasable connection may be a snap connection or a screw connection.
- the adapter housing has a second axis perpendicular to the first axis, and wherein the adapter housing has two opposite connecting elements for connecting the adapter housing with the container housing, opposite along the second axis.
- the connecting elements may be flexible elements providing a releasable connection to the container housing.
- Each flexible element may be at its one end integral with the adapter housing and the opposite flexible end comprising a locking feature.
- the locking feature is a ledge extending in a direction perpendicular to the plane defined by first axis and second axis and projecting along second axis, or the locking feature is a groove extending in a direction perpendicular to the plane defined by first axis and the second axis and being recessed along second axis.
- the push rod is embedded in the adapter housing such that the outermost end surface is flush with a surface of the adapter housing.
- the adapter housing may have a stepped structure so that the push rod is displaceable towards the container.
- the stepped structure may be generally a U-shaped structure.
- the entry port comprises a valve element for connecting the entry port with a syringe.
- the syringe may be a needleless syringe.
- a container for a pharmaceutical composition having a separable and removable adapter for filling and subsequent closing of the container, the adapter as defined in any one of the preceding aspects, the container further comprising a medicament bag, and a port configured for being removably connected with the adapter.
- the medicament bag is a flexible medicament bag, preferably a flat flexible bag.
- the container further comprises a container housing accommodating the medicament bag.
- the port may be part of the medicament bag or part of the container housing.
- the container housing comprises one or more container connecting elements mating with the adapter connecting elements.
- Each container connecting element may comprises a locking feature.
- the locking feature may be a corresponding groove or ledge.
- a container for a flexible bag having an inner space to accommodate a volume of liquid
- the container comprising: a container housing for accommodating the flexible bag; an outlet port for communication of the inner space of the flexible bag with the exterior of the container; and one or more container connecting elements mating with connecting elements of a flexible bag filling adapter.
- each container connecting element comprises a locking feature.
- the container housing has a container housing case and a container housing lid.
- the one or more container locking feature comprise a case locking feature and a lid locking feature.
- the container connecting element is formed as a recess in the circumferential walls of the container housing case and the container housing lid.
- the locking feature may be formed as a ridge at the wall of the recess.
- the container further comprises an adapter for filling and subsequent closing of the flexible bag in the container.
- the adapter comprises: a housing having a cavity with a cavity opening coupleable to a port of the container; a closure element arranged in the cavity; a push rod being arranged at least partially outside the cavity and being movable by a user; the housing having an entry port with an entry port opening in communication with the cavity.
- an adapter for filling and subsequent closing of a pharmaceutical composition container and a container frame comprising: a housing having a first axis, the housing having a cavity with a cavity opening; a closure element arranged in the cavity and displaceable from a first position to a second position, in a direction along the first axis; a push rod being arranged at least partially outside the cavity and being movable by a user in a direction along the first axis for displacing the closure element; the housing having an entry port with an entry port opening in communication with the cavity, at least part of the entry port opening being located axially between the first position of the closure element and the cavity opening when viewed along the first axis; wherein the adapter housing has one or more connecting elements for connecting the adapter housing with the container frame.
- the one or more connecting elements provide a releasable connection between the adapter housing with the container frame.
- the releasable connection is a snap connection or a screw connection.
- One advantage of the invention is that it allows for filling the drug container in multiple scenarios, e.g. in an industrial environment or in a clinical setting.
- Fig. 1 is a perspective view of a container with an adapter according to a first embodiment of the present invention.
- Fig. 2 is a front view of the container with an adapter of Fig. 1 according to the first embodiment of the present invention.
- Fig. 3 shows the medicament bag of the container in communication with the adapter according the first embodiment of the present invention.
- Fig. 4 shows the medicament bag of the container decoupled from the adapter according the first embodiment of the present invention.
- Fig. 5 shows the adapter according to the first embodiment of the present invention.
- Fig. 6 shows an exploded perspective view of the adapter according to the first embodiment of the present invention.
- Fig. 7 shows a perspective bottom view of the housing of the adapter according to the first embodiment of the present invention.
- Fig. 8 shows a different exploded perspective view of the adapter according to the first embodiment of the present invention.
- Fig. 9 shows a perspective top view of the housing of the adapter according to the first embodiment of the present invention.
- Fig.10 shows a perspective cross-sectional view of the housing of the adapter according to the first embodiment of the present invention.
- Fig. 11 shows a perspective view of a different cross-section of the housing of the adapter according to the first embodiment of the present invention.
- Fig. 12 shows a cross-section of an adapter according to a second embodiment of the present invention.
- Fig. 13 illustrates the use of the adapter of the second embodiment of the present invention.
- Fig. 14 illustrates further steps of the use of the adapter of the second embodiment of the present invention.
- Fig. 15 illustrates details of the container according to an embodiment of the present invention.
- Fig. 16 illustrates an exploded perspective view of the container of Fig. 15.
- Fig. 17 illustrates a perspective inner view of the container housing case.
- Fig. 1 is a perspective view of a container 300 with an adapter 100 according to a first embodiment of the present invention.
- Fig. 1 shows the adapter 100 releasably coupled to the container 300.
- the adapter 100 has an entry port and a syringe 400 is shown releasably connected to the adapter 100 at the entry port.
- the container 300 has a container housing 320, and a medicament bag (not shown) is in the container housing 320.
- the medicament bag in the container 300 can be filled from the syringe 400 via the adapter 100.
- Fig. 1 also shows the push rod 140 of the adapter 100 and the connecting elements releasably connecting the adapter 100 to the housing 320 of the container 300.
- the container connecting element 340 is seen. This will be described in more detail below.
- the top surface of the push rod 140 is flush with the top surface of the adapter housing 110.
- the flush configuration is optional, the top surface of the push rod 140 can also protrude from the top surface of the adapter housing 100 or be recessed in relation thereto. The function of the push rod 140 will be described in more detail below.
- Fig. 1 also illustrates the second aspect of the invention.
- the second aspect is a ccontainer 300 for a pharmaceutical composition having a separable and removable adapter 100 for filling and subsequent closing of the container 300, both being pre-assembled.
- the container 300 and the adapter 100 are provided preassembled as a kit set.
- the syringe 400 containing the pharmaceutical composition with which the medicament bag is to be filled is provided separately and is connected by the user to the adapter 100 of the pre-assembled kit.
- the syringe 400 is removed from the adapter 100, and the adapter 100 is decoupled or released from the container 300.
- the adapter 100 with the syringe 400 still being connected to it is removed from the container 300.
- Fig. 2 is a front view of an adapter 100 of Fig. 1 with the container 300 of Fig. 1 according to the first embodiment of the present invention.
- the front view of the adapter 100 is defined as the view showing the entry port 150 (see Fig. 4).
- Fig. 2 also shows that the top surface or outermost end surface 141 of the push rod 140 is flush with the top surface 111 of the adapter housing 110.
- the adapter housing 110 has a first axis A and a second axis B perpendicular to the first axis.
- the first axis is the vertical axis
- the second axis is a horizontal axis from left to right. Reference will be made to these axes below.
- the adapter housing 110 has a connecting element 160 for releasably securing the adapter housing 110 to the container housing 320.
- a connecting element 160 for releasably securing the adapter housing 110 to the container housing 320.
- there are two connecting elements 160 opposed to one another, e.g. in the sense that they are operable in opposing directions - in the illustrated embodiment by being pressed towards one another.
- two connecting element 160 are provided, they are arranged in symmetry with respect to the entry port into the medicament bag. Such symmetrical arrangement allows for a simple coupling of the adapter 100 of the container 300 because the user does not have to care about correct orientation of the adapter 100 with respect to the container 300.
- the adapter housing 110 has a generally rectangular cross section in the vertical plane (e.g., the plane of the drawing of Fig. 2 defined by axes A and B). It may also have a generally rectangular cross-section in the horizontal plane (i.e., the plane to which axis A is perpendicular).
- the two connecting elements 160 are provided at the opposite smaller sides of the adapter housing 110.
- the container 300 also has a generally rectangular cross section in the horizonal and vertical planes.
- alternative shapes are also encompassed by the present invention. For example, a square cross-section of the adapter 100 and/or the container 300 in horizontal and or vertical planes(s) is also envisaged.
- the container 300 has an elliptical, semicircular, or even circular cross section in the horizontal plane.
- the cross section of the adapter 100 might be adapted to such cross section of the container 300, and so the adapter 100 in an alternative embodiment has a circular cross section in the horizontal plane.
- three connecting elements 160 may be provided, spaced from each other by 120° around the vertical center axis, and operable by a user with three fingers.
- Each connecting element 160 has a locking feature 161 that connects to a mating locking feature 341 of the container connecting element 340, although other arrangements are possible.
- the connecting elements 160 a re flexible elements providing a releasable connection to the container housing 320.
- each flexible element is at its one end integral with the adapter housing 110 and the opposite flexible end comprises the locking feature 161.
- the locking feature 161 is a ledge extending in a direction perpendicular to the plane defined by axis A and B and projecting along axis B.
- the locking feature is a groove extending in a direction perpendicular to the plane defined by axis A and B and being recessed along axis B.
- the locking feature 341 of the container 300 is a corresponding, mating groove or ledge.
- Such mating locking features 161, 341 provide a releasable securing of the adapter 100 to the container 300 along the first axis A.
- the locking features 161, 341 are shaped such that a sliding movement along the axis of the entry port 150 (i.e., perpendicular to axis A) is required to couple the adapter 100 to the container 300.
- the connecting elements 160, 340 have a curved shape (curved around the first axis) or helical shape so that the adapter 10 is connected to the container 300 with a rotational movement over some degrees of rotation, bringing the connecting elements 160, 340 slidingly into engagement. With such a configuration the connecting elements 160 of the adapter 100 need not be flexible but can be formed as protrusions of the adapter housing 110.
- Fig. 3 shows the medicament bag of the container 300 in fluid communication with the adapter 100 according the first embodiment of the present invention.
- the container housing 320 is removed so that the medicament bag 310 can be seen.
- Fig. 4 shows the medicament bag 310 of the container released from the adapter 100 according the first embodiment of the present invention.
- the container housing 320 is also not shown, and the adapter 100 is shown in a disconnected state, for example prior to connecting it to the container 300 before filling the medicament bag 310, or after the filling has been completed.
- the medicament bag 310 has a port 330 to which the adapter 100 is couplable at a corresponding coupling element.
- the push rod 140 is shown in its first, for example, initial position where the outer surface 141 is flush with the outer surface 111 of the adapter housing 110.
- Fig. 5 shows the adapter 100 according to the first embodiment of the present invention.
- the adapter 100 is shown in a state where the push rod 140 has already been operated by a user.
- the push rod 140 has been displaced along the first axis towards the medicament bag (not shown). This displacement requires a stepped structure of the adapter housing 110, which will be clearer below.
- Fig. 6 shows an exploded perspective view of the adapter 100 according to the first embodiment of the present invention.
- Fig. 6 shows the adapter housing 110 with the adapter connecting elements 160 with its ledges 161 and the entry port 150.
- Fig. 6 also shows part of a cavity 120 of the adapter housing 110, which cavity 120 is open towards a cavity opening 121 for fluid communication with the medicament bag 310.
- Fig. 6 also shows the push rod 140 in more detail.
- the push rod 140 is at least partially arranged outside the cavity 120 and is movable by a user in a direction along the first axis A for displacing the closure element 130 within the cavity 120.
- the wording "at least partially arranged outside the cavity” refers to a state shown in Fig.
- Fig. 6 further shows O-rings 144, 145, and gasket 146.
- the O-rings 144, 145 are located on push rod 140 and cooperate with an inner surface of the cavity 120 to provide a fluid tight seal. This helps to ensure that the pharmaceutical composition is expelled from the cavity 120 as the medicament container 300 is closed.
- the gasket 146 is located between the adapter 100 and the container 300 and helps to ensure a fluid tight seal between the adapter 100 and the port 330 of the container 300.
- the push rod 140 of this exemplary embodiment has generally a T-shape.
- the vertical part of the T being formed by a generally cylindrical part, and the horizontal part being formed by a flat plate forming the outer surface 141.
- the push rod 140 may have opposing side elements 142 extending parallel to the central vertical part or stem so that the space formed by the push rod 140 is closed and guided by the adapter housing 110.
- one side element may have a recess 143 the shape of which is mating with the shape of the entry port 150 so that upon movement of the push rod 140 there is no conflict with the entry port 150.
- Fig. 6 also shows the stepped structure of the adapter housing 110.
- the stepped structure is generally a U-shaped structure.
- the stepped structure allows for a displacement of the push rod 140 from an initially flush position (as sown in Fig. 1) to the position shown in Fig. 5.
- the flush configuration is a design option, and the push rod 140 can likewise protrude upwards from the surface 111 of the adapter housing 110.
- no stepped structure of the adapter housing 110 is necessary, i.e., the upper surface 111 of the adapter housing is contiguous.
- Fig. 6 shows a valve element 170, for example, a swabable valve, for attaching or connecting or coupling a syringe, for example a needle-free syringe.
- a valve element 170 for example, a swabable valve, for attaching or connecting or coupling a syringe, for example a needle-free syringe.
- Fig. 7 shows a perspective bottom view of the housing 110 of the adapter 100 according to the first embodiment of the present invention.
- the cavity 120 and its arrangement relative to the entry port 150 is clearly seen.
- Fig. 8 shows a different exploded perspective view of the adapter 100 according to the first embodiment of the present invention.
- the entry port opening 151 is seen.
- the entry port 150 is in fluidic communication with the cavity 120 of the adapter housing 110.
- Fig. 9 shows a perspective top view of the housing of the adapter 100 according to the first embodiment of the present invention. Again, the cylindrical cavity 120 is illustrated in this drawing, and the entry port 150.
- Fig. 10 shows a perspective cross-sectional view of the housing 110 of the adapter 100 according to the first embodiment of the present invention.
- the cross section is drawn in the plane formed by the first axis A and a third axis being perpendicular to the first axis A and the second axis B.
- This cross-sectional view shows the entry port 150 with its entry port channel 152 and the entry port opening 151.
- the axis of the entry port channel 152 is perpendicular to the axis of the cavity 120.
- the opening 151 enters into the cavity 120 at a location along first axis A that is between the closure element 130 in its first, for example initial, position, and the cavity opening 121.
- the opening 151 is located axially between the first position of the closure element 130 and the cavity opening 121 when viewed along the first axis A.
- the axial position of the opening 151 is preferably such that the closure element 130 when being in its initial position does not overlap with the opening 151, and that the closure element 130 in its final position does also not overlap with the opening 151.
- partial overlap in one or both of these positions of the closure element 130 with the opening 151 is encompassed by the present disclosure.
- the cavity 120 has a portion of slightly larger diameter towards the cavity opening 121. This facilitates mating with the port 330 of the medicament bag 310.
- the cavity 120 also has a portion of slightly larger diameter towards the other end, e.g. the end opposite to that of the cavity opening 121, and on a side of the entry port 150 that is away from the cavity opening. This helps to keep the closure element 130 in place before using the adapter 100.
- Fig. 11 shows a perspective view of a different cross-section of the housing of the adapter according to the first embodiment of the present invention. This cross section is drawn in a plane formed by the first axis A and the second axis B. The opening 151 connecting the entry port channel 152 with the cavity is seen, and also the cavity opening 121.
- Fig. 12 shows a cross-section of an adapter 500 according to a second embodiment of the present invention.
- the adapter 500 has a different configuration.
- the adapter 500 of this embodiment has a housing 510 that is generally elongate, and in this preferred embodiment at least is generally cylindrical in shape.
- the housing 510 defines a cavity 520 that has a cavity opening 521 at the end facing the medicament bag 310 or the medicament container 300, respectively, when the adapter 500 is in use.
- the housing 510 has a structure for mounting the adapter 500 to the container 300.
- the adapter 500 is shown coupled to the port 330 of the medicament bag 310 in the container 300.
- a closure element 530 is located in the cavity 520.
- a push rod 540 which may be T-shaped in cross section, is shown at least partially arranged outside the cavity 520 (and at least partially within the cavity 520) and is movable by a user in a direction along the first axis A for displacing the closure element 530 within the cavity 520.
- the housing 510 has wings 560 for being gripped by a user during use of the adapter 500.
- the housing 510 has an entry port 550 with an entry port opening 551 and an entry port channel 552. In the illustrated embodiment, the entry port channel 552 is closed with a septum 555.
- the entry port channel 552 is shown inclined with regard to the first axis A.
- at least part of the length of entry port channel 552 is inclined with respect to the first axis A (or the second axis B).
- the axis of at least part of the length of entry port channel 552 lies in the plane defined by axes A and B.
- the axis of at least part of the length of entry port channel 552 may further be inclined with regard to the plane defined by axes A and B.
- the entry port channel 552 may also be oriented perpendicular to the first axis A, like it is shown in the first embodiment, i.e., along the second axis B.
- the entry port channel 552 may be oriented perpendicular to the first axis A and also inclined with respect to the plane defined by axes A and B.
- the opening 551 enters into the cavity 520 at a location along first axis A that is between the closure element 530 in its first, for example initial, position, and the cavity opening 521 .
- the opening 551 is located axially between the first position of the closure element 530 and the cavity opening 521 when viewed along the first axis A.
- the axial position of the opening 551 is preferably such that the closure element 530 when being in its initial position does not overlap with the opening 551, and that the closure element 530 in its final position does also not overlap with the opening 551.
- partial overlap in one or both of these positions of the closure element 530 with the opening 551 is encompassed by the present disclosure.
- the container 300 is (pre- )assembled with the adapter 500 for the pharmacy or clinic filling scenario.
- This assembly can be packed as a single piece.
- the adapter 500 contains the closure 530 which is needed to close the system.
- the design of adapter 500 is like a syringe, but instead of a plunger in a syringe the closure element 530 in the adapter 500 is moved by the push rod 540 inside the cavity 520.
- a connection to the adapter cavity 520 by the entry port 550 allows the filling of the drug container 300.
- Fig.12 shows a septum 555 which can be pierced with a cannula multiple time.
- the septum 555 is arranged in the entry port channel 552 as a closure of the entry port 550 at the end opposite to the entry port opening 551.
- a Luer connection or both, other non-Luer connections, or other suitable connectors.
- a cooperating connection may be provided for a closed-system transfer device (CSTD) or components thereof to avoid user exposure to a medication filled into the drug container using the apparatus.
- CSTD closed-system transfer device
- Fig. 13 illustrates the use of the adapter 500 of the second embodiment of the present invention.
- the left-hand figure shows the (pre-)assembled adapter 500 and drug container 300.
- the next stage of use is shown in the right-hand figure. It illustrates how the septum 555 is pierced by the filling syringe, and the medicament is transferred via the cavity 520 and through the cavity opening 521 into the medicament container 300 (medicament flow highlighted by the two arrows).
- the syringe is removed, as by withdrawal, unscrewing, etc. If needed, one or more further components can be inserted this way into the container 300. Thus, this process may be repeated any number of times if necessary.
- a 50ml syringe is used with the apparatus, and a 100ml dose is desired in the medicament bag, the process described may be repeated twice.
- two 50ml syringes could be each filled with a different medication (for instance, a biologic medication and normal saline) and each added to the bag in sequence.
- Fig. 14 illustrates further steps of the use of the adapter 500 of the second embodiment of the present invention.
- Fig. 14 shows the stoppering and the removal of the adapter 500 from the drug container.
- the push rod 540 of the adapter 500 is pressed.
- the closure element 530 acts as a plunger and pushes all drug elements remaining in the cavity 520 into the drug container 300.
- the user may push with the thumb on the push rod 540 and concurrently holds the two wings 560 with index finger and middle finger to apply a force on the push rod 540 (see left-hand figure).
- the closure element 530 is connected to the port, it for example snaps in, and seals and closes the drug container 300.
- the connection between the closure element 530 and the adapter 500 releases and the adapter 500 can be removed from the drug container 300 and discarded.
- the closure element 530 is now arranged on the drug container 300.
- the right-hand figure shows that the adapter housing 510 is already lifted a certain distance from the drug container 300.
- Figs. 15 to 17 show the container 300 according to an aspect of the present invention in more detail.
- the container 300 is adapted to accommodate the medicament bag 310.
- the medicament bag 310 is flexible.
- the medicament bag 310 has an inner space to accommodate a volume of liquid.
- the container 300 comprises a container housing 320 for accommodating the flexible bag 310, and in the illustrated embodiment supporting the medicament bag 310.
- the container 300 also has an entry port (or outlet port, respectively) 343 for accommodating or receiving the port 330 of the medicament bag 310 for communication of the inner space of the medicament bag 310 with the exterior of the container 300.
- the inlet port 343 is formed as a through hole.
- the container 300 has a container housing case or container frame 322 and a container housing lid 321.
- the lid 321 When the lid 321 is connected to the case or frame 322, the inner space for the medicament bag 310 is provided.
- the lid 321 is a preferred element, the container 300 could accommodate the flexible bag 310 without being closed by lid 321.
- the container housing lid 321 and the container housing case 322 each have a perimeter wall 323, 324.
- the perimeter walls 323, 324 provide rigidity to the container housing 320.
- the container 300 also has one or more container connecting elements 340.
- the connecting elements 340 are adapted to mate with corresponding connecting elements of a flexible bag filling adapter, such as the adapter 100,500 of the present disclosure.
- two connecting elements 340 are provided. These are preferably arranged one on each side of the inlet port 343.
- each container connecting element 340 comprises a locking feature 341.
- the one or more container locking features 341 comprise a case locking feature 3411 and a lid locking feature 3412.
- the adapter 100, 500 is coupled or connected to the container housing case 322 and the container housing lid 321.
- This allows for a coupling direction along the axis of the port 343.
- the locking features 3411 and 3412 on the lid and on the case provide for a snap-on connection of the adapter on the container 300.
- the locking feature is provided only in the container housing case 322 and not in the container housing lid 321. With such a configuration the adapter 100, 500 can be coupled to the container 300 for example in a sliding movement perpendicular to the axis of the port 343.
- the container connecting element 340 is formed as a recess in the circumferential walls 323, 324 of the container housing case 322 and the container housing lid 321.
- the respective locking feature 341 is preferably formed as a ridge or ledge at the wall of the recess. The ridge or ledge can mate with a corresponding ledge on the adapter connecting element to releasably couple the two components together.
- the adapter 100, 500, adapter housing 110, 510, and push rod 140, 540 may be constructed of one or more rigid plastic materials, such as polypropylene, polycarbonate, acrylonitrile butadiene styrene, polyamide, polystyrene, or combinations thereof.
- portions of adapter housing 110, 510, and push rod 140, 540 may be over-molded on the side closest to the container 300 body with a soft, compliant material, such as thermoplastic elastomer or thermoplastic polyurethane, to improve comfort for a user of the device during filling of the container 300 or placement of the closure element 130,530.
- the devices described herein can be used forthe treatment and/or prophylaxis of one or more of many different types of disorders.
- Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn's disease and ulcerative colitis), hypercholesterolaemia and/or dyslipidemia, cardiovascular disease, diabetes (e.g.
- psoriasis psoriatic arthritis
- spondyloarthritis spondyloarthritis
- hidradenitis suppurativa Sjogren's syndrome
- migraine cluster headache
- multiple sclerosis neuromyelitis optica spectrum disorder, anaemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anaemia, hereditary angioedema, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, Behcet's disease, hemophagocytic lymphohistiocytosis, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid eye disease, nasal polyps, transplant, acute
- Exemplary types of drugs that could be included in the delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-drug conjugates, neutralizing antibodies, reversal agents, radioligand therapies, radioisotopes and/or nuclear medicines, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, nucleotides, protein analogues, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies.
- Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
- immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
- Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as human epidermal growth factor receptor 2 (HER-2) receptor modulators, interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-1 (GLP-1) modulators, glucose-dependent insulinotropic polypeptide (G I P) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, Cl esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B-cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR) modulators, cluster of differentiation 79B (CD79B)
- Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to: etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, erenumab, galcanezumab, fremanezumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-la, interferon beta-lb, peginterferon beta-la, sumatriptan, darbepoetin alfa, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crizanlizumab-
- Exemplary drugs that could be included in the delivery devices described herein may also include, but are not limited to, oncology treatments such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab- pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90- Yttrium-ibritum
- Exemplary drugs that could be included in the delivery devices described herein include “generic” or biosimilar equivalents of any of the foregoing, and the foregoing molecular names should not be construed as limiting to the "innovator” or “branded” version of each, as in the non-limiting example of innovator medicament adalimumab and biosimilars such as adalimumab-afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.
- Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, those used for adjuvant or neoadjuvant chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
- adjuvant or neoadjuvant chemotherapy such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
- Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
- Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g. hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, antiseptics, anticoagulants, fibrinolytics (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombolytics, or diluents such as sterile water for injection (SWFI), 0.9% Normal Saline, 0.45% normal saline, 5% dextrose in water, 5% dextrose in 0.45% normal saline, Lactated Ringer's solution, Heparin Lock Flush solution, 100 U/mL Heparin Lock Flush Solution, or
- compositions including, but not limited to, any drug described herein are also contemplated for use in the delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier.
- Such formulations may include one or more other active ingredients (e.g., as a combination of one or more active drugs), or may be the only active ingredient present, and may also include separately administered or co-formulated dispersion enhancers (e.g. an animal-derived, human-derived, or recombinant hyaluronidase enzyme), concentration modifiers or enhancers, stabilizers, buffers, or other excipients.
- Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOXG, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MIN E, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CH P, GCVP, D
- Adapter (100, 500) for filling and subsequent closing of a pharmaceutical composition container (300), the adapter (100, 500) comprising: a housing (110, 510) having a first axis (A), the housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521) coupleable to a port of the container (300); a closure element (130, 530) arranged in the cavity (120, 520) and displaceable from a first position to a second position, in a direction along the first axis (A); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user in a direction along the first axis (A) for displacing the closure element (130, 530); the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520), at least part of the entry port opening (151, 551) being located
- the entry port (150, 550) comprises one or more of a self-sealing elastomeric septum, needleless connector, female Luer connection, male Luer connection, Luer access valve, Luer activated device, or combinations thereof, at the end opposite to the cavity opening (151, 551).
- the closure element (130) is a plunger for expelling fluid from the cavity (120).
- each flexible element is at its one end integral with the adapter housing (110) and the opposite flexible end comprising a locking feature (161).
- Container (300) for a pharmaceutical composition having a separable and removable adapter (100, 500) for filling and subsequent closing of the container (300), the adapter (100, 500) as defined in any one of the preceding clauses, the container (300) further comprising: a medicament bag (310), and a port (330) configured for being removably connected with the adapter (100).
- Container (300) according to clause 35, wherein the medicament bag (310) is a flexible medicament bag, preferably a flat flexible bag.
- Container (300) according to clause 36, wherein the container (300) further comprises a container housing (320) accommodating the medicament bag (310).
- Container (300) according to clause 37, wherein the port (330) is part of the medicament bag (310) or part of the container housing (320).
- Container (300) according to clause 37 or 38, wherein the container housing (320) comprises one or more container connecting elements (340) mating with the adapter connecting elements (160).
- each container connecting element (340) comprises a locking feature (341).
- Container (300) for a flexible bag (310) having an inner space to accommodate a volume of liquid comprising: a container housing (320) for accommodating the flexible bag (310); an outlet port (343) for communication of the inner space of the flexible bag (310) with the exterior of the container (300); and one or more container connecting elements (340) mating with connecting elements (160) of a flexible bag filling adapter (100).
- each container connecting element (340) comprises a locking feature (341).
- Container (300) according to clause 42 or 43, wherein the container housing (300) has a container housing case (322) and a container housing lid (321).
- Container (300) according to any one of clauses 42 to 47, further comprising an adapter (100, 500) for filling and subsequent closing of the flexible bag (310) in the container (300).
- the adapter (100, 500) comprises: a housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521) coupleable to a port of the container (300); a closure element (130, 530) arranged in the cavity (120, 520); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user; the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520).
- the adapter (100, 500) comprising: a housing (110, 510) having a first axis (A), the housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521); a closure element (130, 530) arranged in the cavity (120, 520) and displaceable from a first position to a second position, in a direction along the first axis (A); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user in a direction along the first axis (A) for displacing the closure element (130, 530); the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520), at least part of the entry port opening (151, 551) being
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The invention provides an adapter for filing and subsequent closing of a pharmaceutical composition container, the adapter comprising a housing having a first axis, the housing having a cavity with an opening coupleable to a port of the container; a closure element arranged in the cavity and displaceable from a first position to a second position, in a direction along the first axis; a push rod being at least partially arranged outside the cavity and being movable by a user in a direction along the first axis for displacing the closure element; the housing having an entry port with an entry port opening in communication with the cavity, at least part of the entry port opening being located axially between the first position of the closure element and the opening when viewed along the first axis.
Description
Adapter for filling and subsequent closing of a pharmaceutical composition container, and container with adapter
Technical Field
The present disclosure relates to the filling of a drug container. The disclosure is particularly, but not exclusively, applicable to an adapter for filling and subsequently closing a pharmaceutical composition container, such as a flat medicament bag made of plastics.
Background
An exemplary drug container is a flat medicament bag made of one or more plastics showing excellent barrier properties that may allow long storage like glass vials. Such an exemplary drug container may contain three main parts: a film of one or more layers, which is welded to form a bag; a port, which contains interfaces and provides access to the interior of the bag; and a closure to close the port.
US 8 763 798 B2 relates to a closure for filling and sealing receptacles containing medicinal fluids, a method for filling a receptacle with a medicinal fluid and sealing the receptacle. The closure used in the method comprises a mounting piece that may be attached to the receptacle and a connector piece that may be connected to a connector piece of a filling device. A closure body is arranged between the mounting piece and the connector piece, in which a closure piece for sealing the closure sits. The closure piece may be slid between a position sealing the closure and a position which opens the closure. The closure is sealed tight with a removable protective cap. The receptacle is filled through the closure in a clean room. After filling, the closure is sealed by pressing the closure piece into the closure.
Such drug containers have generally been developed to be filled in industrial environment on an automated filling station in aseptic environment, in order to minimize the risk of contamination. However, this can be inconvenient and involve undesirable logistics.
Summary of the Disclosure
An object of the invention is to provide a filling tool that allows for the filling of a drug container and to provide a medicament bag designed for being filled in either an industrial environment or in a clinical setting, such as a treatment room or pharmacy, by a medical practitioner, nurse or pharmacist. This object is achieved with an adapter according to independent claim 1, a container with an adapter according to independent claim 11 or 12, or a combination according to claim 15. Preferred embodiments are defined in the dependent claims.
According to a first aspect of the present disclosure, there is provided an adapter for filling and subsequent closing of a pharmaceutical composition container, the adapter comprising: a housing having a first axis, the housing having a cavity with a cavity opening coupleable to a port of the container; a closure element arranged in the cavity and displaceable from a first position to a second position, in a direction along the first axis; a push rod being arranged at least partially outside the cavity and being movable by a user in a direction along the first axis for displacing the closure element; the housing having an entry port with an entry port opening in communication with the cavity, at least part of the entry port opening being located axially between the first position of the closure element and the cavity opening when viewed along the first axis.
According to a preferred aspect, the entry port has an entry port channel, at least part of the length of which is perpendicular to or is inclined with respect to the first axis.
According to a preferred aspect, the adaptor has two opposing sides along the first axis, one side being the side where the adapter is connectable to a port of the container, the other, second side for being held and/or operated by a user.
According to a preferred aspect, the push rod has a generally T-shape in cross-section along the first axis.
According to a preferred aspect, the adapter further comprises a pierceable septum in the entry port channel.
According to a preferred aspect, the entry port comprises one or more of a self-sealing elastomeric septum, needleless connector, female Luer connection, male Luer connection, Luer access valve, Luer activated device, or combinations thereof, at the end opposite to the cavity opening.
According to a preferred aspect, the entry port is configured to cooperate with at least one or more of a male Luer connector, female Luer connector, vial adapter, vial spike, IV tubing set spike, or combinations thereof.
According to a preferred aspect, the entry port is configured to cooperate with at least one closed-system transfer device or component.
According to a preferred aspect, the closure element is adapted to seal the port of the container.
According to a preferred aspect, the closure element is configured to remove substantially all of a drug from the cavity.
According to a preferred aspect, the closure element is configured to remove substantially all of a drug from the cavity after filling and displacement of the closure element.
According to a preferred aspect, the closure element is adapted to enter into a connection with the port of the container and to be released from the adapter upon removal of the adapter from the container.
According to a preferred aspect, the closure element is a plunger for expelling fluid from the cavity.
According to a preferred aspect, the closure element is a substantially elastomeric material.
According to a preferred aspect, the closure element is a blend of thermoplastic elastomer and an olefin polymer.
According to a preferred aspect, the cavity is made from an olefin polymer.
According to a preferred aspect, the adapter is configured such that one or more portions of the adapter or the housing are removed from the container after filling.
According to a preferred aspect, the adapter is configured such that one or more portions of the adapter or the housing are removed from the container after filling and displacement of the closure element.
According to a preferred aspect, the adapter housing has a protruding structure for being gripped by a user during use. The adapter housing may be generally elongate along the direction of the first axis, preferably generally cylindrical.
According to a preferred aspect, the push rod protrudes along the first axis from the adapter housing (510) at the side for being held and/or operated by a user.
According to a preferred aspect, the push rod protrudes along the first axis from the adapter housing at the side for being held and/or operated by a user.
According to a preferred aspect, the adapter housing has one or more connecting elements for connecting the adapter housing with the container housing. The one or more connecting elements may provide a releasable connection between the adapter housing with the container housing. The releasable connection may be a snap connection or a screw connection.
According to a preferred aspect, the adapter housing has a second axis perpendicular to the first axis, and wherein the adapter housing has two opposite connecting elements for connecting the adapter housing with the container housing, opposite along the second axis. The connecting elements may be flexible elements providing a releasable connection to the
container housing. Each flexible element may be at its one end integral with the adapter housing and the opposite flexible end comprising a locking feature.
According to a preferred aspect, the locking feature is a ledge extending in a direction perpendicular to the plane defined by first axis and second axis and projecting along second axis, or the locking feature is a groove extending in a direction perpendicular to the plane defined by first axis and the second axis and being recessed along second axis.
According to a preferred aspect, the push rod is embedded in the adapter housing such that the outermost end surface is flush with a surface of the adapter housing. The adapter housing may have a stepped structure so that the push rod is displaceable towards the container. The stepped structure may be generally a U-shaped structure.
According to a preferred aspect, the entry port comprises a valve element for connecting the entry port with a syringe. The syringe may be a needleless syringe.
According to another aspect of the present disclosure, there is provided a container for a pharmaceutical composition having a separable and removable adapter for filling and subsequent closing of the container, the adapter as defined in any one of the preceding aspects, the container further comprising a medicament bag, and a port configured for being removably connected with the adapter.
According to a preferred aspect, the medicament bag is a flexible medicament bag, preferably a flat flexible bag.
According to a preferred aspect, the container further comprises a container housing accommodating the medicament bag. The port may be part of the medicament bag or part of the container housing.
According to a preferred aspect, the container housing comprises one or more container connecting elements mating with the adapter connecting elements. Each container
connecting element may comprises a locking feature. The locking feature may be a corresponding groove or ledge.
According to another aspect of the present disclosure, there is provided a container for a flexible bag having an inner space to accommodate a volume of liquid, the container comprising: a container housing for accommodating the flexible bag; an outlet port for communication of the inner space of the flexible bag with the exterior of the container; and one or more container connecting elements mating with connecting elements of a flexible bag filling adapter.
According to a preferred aspect, each container connecting element comprises a locking feature.
According to a preferred aspect, the container housing has a container housing case and a container housing lid.
According to a preferred aspect, the one or more container locking feature comprise a case locking feature and a lid locking feature.
According to a preferred aspect, the container connecting element is formed as a recess in the circumferential walls of the container housing case and the container housing lid. The locking feature may be formed as a ridge at the wall of the recess.
According to a preferred aspect, the container further comprises an adapter for filling and subsequent closing of the flexible bag in the container.
According to a preferred aspect, the adapter comprises: a housing having a cavity with a cavity opening coupleable to a port of the container; a closure element arranged in the cavity; a push rod being arranged at least partially outside the cavity and being movable by a user;
the housing having an entry port with an entry port opening in communication with the cavity.
According to a further aspect of the present disclosure, there is provided a combination of an adapter for filling and subsequent closing of a pharmaceutical composition container and a container frame, the adapter comprising: a housing having a first axis, the housing having a cavity with a cavity opening; a closure element arranged in the cavity and displaceable from a first position to a second position, in a direction along the first axis; a push rod being arranged at least partially outside the cavity and being movable by a user in a direction along the first axis for displacing the closure element; the housing having an entry port with an entry port opening in communication with the cavity, at least part of the entry port opening being located axially between the first position of the closure element and the cavity opening when viewed along the first axis; wherein the adapter housing has one or more connecting elements for connecting the adapter housing with the container frame.
According to a preferred aspect, the one or more connecting elements provide a releasable connection between the adapter housing with the container frame.
According to a preferred aspect, the releasable connection is a snap connection or a screw connection.
One advantage of the invention is that it allows for filling the drug container in multiple scenarios, e.g. in an industrial environment or in a clinical setting.
Brief Description of Drawings
The invention will be described with reference to the drawings in which:
Fig. 1 is a perspective view of a container with an adapter according to a first embodiment of the present invention.
Fig. 2 is a front view of the container with an adapter of Fig. 1 according to the first embodiment of the present invention.
Fig. 3 shows the medicament bag of the container in communication with the adapter according the first embodiment of the present invention.
Fig. 4 shows the medicament bag of the container decoupled from the adapter according the first embodiment of the present invention.
Fig. 5 shows the adapter according to the first embodiment of the present invention.
Fig. 6 shows an exploded perspective view of the adapter according to the first embodiment of the present invention.
Fig. 7 shows a perspective bottom view of the housing of the adapter according to the first embodiment of the present invention.
Fig. 8 shows a different exploded perspective view of the adapter according to the first embodiment of the present invention.
Fig. 9 shows a perspective top view of the housing of the adapter according to the first embodiment of the present invention.
Fig.10 shows a perspective cross-sectional view of the housing of the adapter according to the first embodiment of the present invention.
Fig. 11 shows a perspective view of a different cross-section of the housing of the adapter according to the first embodiment of the present invention.
Fig. 12 shows a cross-section of an adapter according to a second embodiment of the present invention.
Fig. 13 illustrates the use of the adapter of the second embodiment of the present invention.
Fig. 14 illustrates further steps of the use of the adapter of the second embodiment of the present invention.
Fig. 15 illustrates details of the container according to an embodiment of the present invention.
Fig. 16 illustrates an exploded perspective view of the container of Fig. 15.
Fig. 17 illustrates a perspective inner view of the container housing case.
Description of Embodiments
Fig. 1 is a perspective view of a container 300 with an adapter 100 according to a first embodiment of the present invention. Fig. 1 shows the adapter 100 releasably coupled to the container 300. The adapter 100 has an entry port and a syringe 400 is shown releasably connected to the adapter 100 at the entry port. The container 300 has a container housing 320, and a medicament bag (not shown) is in the container housing 320. The medicament bag in the container 300 can be filled from the syringe 400 via the adapter 100.
Fig. 1 also shows the push rod 140 of the adapter 100 and the connecting elements releasably connecting the adapter 100 to the housing 320 of the container 300. In Fig. 1, the container connecting element 340 is seen. This will be described in more detail below. It can also be seen that in this embodiment the top surface of the push rod 140 is flush with the top surface of the adapter housing 110. However, the flush configuration is optional, the top surface of the push rod 140 can also protrude from the top surface of the adapter housing 100 or be recessed in relation thereto. The function of the push rod 140 will be described in more detail below.
Fig. 1 also illustrates the second aspect of the invention. The second aspect is a ccontainer 300 for a pharmaceutical composition having a separable and removable adapter 100 for filling and subsequent closing of the container 300, both being pre-assembled. Thus, according to this aspect of the invention the container 300 and the adapter 100 are provided preassembled as a kit set. The syringe 400 containing the pharmaceutical composition with which the medicament bag is to be filled is provided separately and is connected by the user to the adapter 100 of the pre-assembled kit. After the pharmaceutical composition has been filled into the medicament bag and the medicament bag has been closed, the syringe 400 is removed from the adapter 100, and the adapter 100 is decoupled or released from the container 300. Alternatively, the adapter 100 with the syringe 400 still being connected to it is removed from the container 300.
Fig. 2 is a front view of an adapter 100 of Fig. 1 with the container 300 of Fig. 1 according to the first embodiment of the present invention. The front view of the adapter 100 is defined as the view showing the entry port 150 (see Fig. 4). Fig. 2 also shows that the top surface or outermost end surface 141 of the push rod 140 is flush with the top surface 111 of the adapter
housing 110. The adapter housing 110 has a first axis A and a second axis B perpendicular to the first axis. In the view of Fig.2, the first axis is the vertical axis, and the second axis is a horizontal axis from left to right. Reference will be made to these axes below.
The adapter housing 110 has a connecting element 160 for releasably securing the adapter housing 110 to the container housing 320. In the illustrated embodiment, there are two connecting elements 160, opposed to one another, e.g. in the sense that they are operable in opposing directions - in the illustrated embodiment by being pressed towards one another. Preferably, in case two connecting element 160 are provided, they are arranged in symmetry with respect to the entry port into the medicament bag. Such symmetrical arrangement allows for a simple coupling of the adapter 100 of the container 300 because the user does not have to care about correct orientation of the adapter 100 with respect to the container 300.
In the illustrated embodiment, the adapter housing 110 has a generally rectangular cross section in the vertical plane (e.g., the plane of the drawing of Fig. 2 defined by axes A and B). It may also have a generally rectangular cross-section in the horizontal plane (i.e., the plane to which axis A is perpendicular). The two connecting elements 160 are provided at the opposite smaller sides of the adapter housing 110. In this illustrated example, the container 300 also has a generally rectangular cross section in the horizonal and vertical planes. However, alternative shapes are also encompassed by the present invention. For example, a square cross-section of the adapter 100 and/or the container 300 in horizontal and or vertical planes(s) is also envisaged. As a further example, the container 300 has an elliptical, semicircular, or even circular cross section in the horizontal plane. The cross section of the adapter 100 might be adapted to such cross section of the container 300, and so the adapter 100 in an alternative embodiment has a circular cross section in the horizontal plane. In such an alternative embodiment, three connecting elements 160 may be provided, spaced from each other by 120° around the vertical center axis, and operable by a user with three fingers.
Each connecting element 160 has a locking feature 161 that connects to a mating locking feature 341 of the container connecting element 340, although other arrangements are possible. The connecting elements 160 a re flexible elements providing a releasable connection to the container housing 320. In the illustrated embodiment, each flexible element is at its
one end integral with the adapter housing 110 and the opposite flexible end comprises the locking feature 161. The locking feature 161 is a ledge extending in a direction perpendicular to the plane defined by axis A and B and projecting along axis B. Alternatively, the locking feature is a groove extending in a direction perpendicular to the plane defined by axis A and B and being recessed along axis B. The locking feature 341 of the container 300 is a corresponding, mating groove or ledge.
Such mating locking features 161, 341 provide a releasable securing of the adapter 100 to the container 300 along the first axis A. Alternatively, the locking features 161, 341 are shaped such that a sliding movement along the axis of the entry port 150 (i.e., perpendicular to axis A) is required to couple the adapter 100 to the container 300. As a further alternative, the connecting elements 160, 340 have a curved shape (curved around the first axis) or helical shape so that the adapter 10 is connected to the container 300 with a rotational movement over some degrees of rotation, bringing the connecting elements 160, 340 slidingly into engagement. With such a configuration the connecting elements 160 of the adapter 100 need not be flexible but can be formed as protrusions of the adapter housing 110.
Fig. 3 shows the medicament bag of the container 300 in fluid communication with the adapter 100 according the first embodiment of the present invention. In this drawing, the container housing 320 is removed so that the medicament bag 310 can be seen.
Fig. 4 shows the medicament bag 310 of the container released from the adapter 100 according the first embodiment of the present invention. In this drawing, the container housing 320 is also not shown, and the adapter 100 is shown in a disconnected state, for example prior to connecting it to the container 300 before filling the medicament bag 310, or after the filling has been completed. The medicament bag 310 has a port 330 to which the adapter 100 is couplable at a corresponding coupling element. In Fig. 3 and in Fig. 4 the push rod 140 is shown in its first, for example, initial position where the outer surface 141 is flush with the outer surface 111 of the adapter housing 110.
Fig. 5 shows the adapter 100 according to the first embodiment of the present invention. In this drawing, the adapter 100 is shown in a state where the push rod 140 has already been
operated by a user. The push rod 140 has been displaced along the first axis towards the medicament bag (not shown). This displacement requires a stepped structure of the adapter housing 110, which will be clearer below.
Fig. 6 shows an exploded perspective view of the adapter 100 according to the first embodiment of the present invention. Fig. 6 shows the adapter housing 110 with the adapter connecting elements 160 with its ledges 161 and the entry port 150. Fig. 6 also shows part of a cavity 120 of the adapter housing 110, which cavity 120 is open towards a cavity opening 121 for fluid communication with the medicament bag 310. Fig. 6 also shows the push rod 140 in more detail. The push rod 140 is at least partially arranged outside the cavity 120 and is movable by a user in a direction along the first axis A for displacing the closure element 130 within the cavity 120. The wording "at least partially arranged outside the cavity" refers to a state shown in Fig. 1, for example, where the push rod 140 is in its initial position. Upon moving it towards the medicament bag to reach a state as shown in Fig. 5, the push rod 140 is moved into the cavity 120 to displace the closure element 130. Fig. 6 further shows O-rings 144, 145, and gasket 146. The O-rings 144, 145 are located on push rod 140 and cooperate with an inner surface of the cavity 120 to provide a fluid tight seal. This helps to ensure that the pharmaceutical composition is expelled from the cavity 120 as the medicament container 300 is closed. The gasket 146 is located between the adapter 100 and the container 300 and helps to ensure a fluid tight seal between the adapter 100 and the port 330 of the container 300.
In cross-section, the push rod 140 of this exemplary embodiment has generally a T-shape. The vertical part of the T being formed by a generally cylindrical part, and the horizontal part being formed by a flat plate forming the outer surface 141. In addition, the push rod 140 may have opposing side elements 142 extending parallel to the central vertical part or stem so that the space formed by the push rod 140 is closed and guided by the adapter housing 110. As shown in Fig. 6, one side element may have a recess 143 the shape of which is mating with the shape of the entry port 150 so that upon movement of the push rod 140 there is no conflict with the entry port 150.
Fig. 6 also shows the stepped structure of the adapter housing 110. The stepped structure is generally a U-shaped structure. The stepped structure allows for a displacement of the push
rod 140 from an initially flush position (as sown in Fig. 1) to the position shown in Fig. 5. However, as described above, the flush configuration is a design option, and the push rod 140 can likewise protrude upwards from the surface 111 of the adapter housing 110. With such configuration, no stepped structure of the adapter housing 110 is necessary, i.e., the upper surface 111 of the adapter housing is contiguous.
Furthermore, Fig. 6 shows a valve element 170, for example, a swabable valve, for attaching or connecting or coupling a syringe, for example a needle-free syringe.
Fig. 7 shows a perspective bottom view of the housing 110 of the adapter 100 according to the first embodiment of the present invention. In the bottom view of Fig. 7, the cavity 120 and its arrangement relative to the entry port 150 is clearly seen.
Fig. 8 shows a different exploded perspective view of the adapter 100 according to the first embodiment of the present invention. In this drawing, the entry port opening 151 is seen. At the entry port opening 151, the entry port 150 is in fluidic communication with the cavity 120 of the adapter housing 110.
Fig. 9 shows a perspective top view of the housing of the adapter 100 according to the first embodiment of the present invention. Again, the cylindrical cavity 120 is illustrated in this drawing, and the entry port 150.
Fig. 10 shows a perspective cross-sectional view of the housing 110 of the adapter 100 according to the first embodiment of the present invention. The cross section is drawn in the plane formed by the first axis A and a third axis being perpendicular to the first axis A and the second axis B. This cross-sectional view shows the entry port 150 with its entry port channel 152 and the entry port opening 151. In this embodiment, the axis of the entry port channel 152 is perpendicular to the axis of the cavity 120.
The opening 151 enters into the cavity 120 at a location along first axis A that is between the closure element 130 in its first, for example initial, position, and the cavity opening 121. In other words, the opening 151 is located axially between the first position of the closure
element 130 and the cavity opening 121 when viewed along the first axis A. The axial position of the opening 151 is preferably such that the closure element 130 when being in its initial position does not overlap with the opening 151, and that the closure element 130 in its final position does also not overlap with the opening 151. However, partial overlap in one or both of these positions of the closure element 130 with the opening 151 is encompassed by the present disclosure.
The cavity 120 has a portion of slightly larger diameter towards the cavity opening 121. This facilitates mating with the port 330 of the medicament bag 310. The cavity 120 also has a portion of slightly larger diameter towards the other end, e.g. the end opposite to that of the cavity opening 121, and on a side of the entry port 150 that is away from the cavity opening. This helps to keep the closure element 130 in place before using the adapter 100.
Fig. 11 shows a perspective view of a different cross-section of the housing of the adapter according to the first embodiment of the present invention. This cross section is drawn in a plane formed by the first axis A and the second axis B. The opening 151 connecting the entry port channel 152 with the cavity is seen, and also the cavity opening 121.
Fig. 12 shows a cross-section of an adapter 500 according to a second embodiment of the present invention. In this embodiment, the adapter 500 has a different configuration.
The adapter 500 of this embodiment has a housing 510 that is generally elongate, and in this preferred embodiment at least is generally cylindrical in shape. The housing 510 defines a cavity 520 that has a cavity opening 521 at the end facing the medicament bag 310 or the medicament container 300, respectively, when the adapter 500 is in use. At the cavity opening 521 the housing 510 has a structure for mounting the adapter 500 to the container 300. In Fig. 12, the adapter 500 is shown coupled to the port 330 of the medicament bag 310 in the container 300. A closure element 530 is located in the cavity 520. A push rod 540, which may be T-shaped in cross section, is shown at least partially arranged outside the cavity 520 (and at least partially within the cavity 520) and is movable by a user in a direction along the first axis A for displacing the closure element 530 within the cavity 520. The housing 510 has wings 560 for being gripped by a user during use of the adapter 500.
The housing 510 has an entry port 550 with an entry port opening 551 and an entry port channel 552. In the illustrated embodiment, the entry port channel 552 is closed with a septum 555.
The entry port channel 552 is shown inclined with regard to the first axis A. For example, at least part of the length of entry port channel 552 is inclined with respect to the first axis A (or the second axis B). Thus, the axis of at least part of the length of entry port channel 552 lies in the plane defined by axes A and B. In an alternative embodiment, the the axis of at least part of the length of entry port channel 552 may further be inclined with regard to the plane defined by axes A and B. However, the entry port channel 552 may also be oriented perpendicular to the first axis A, like it is shown in the first embodiment, i.e., along the second axis B. In a further alternative embodiment, the entry port channel 552 may be oriented perpendicular to the first axis A and also inclined with respect to the plane defined by axes A and B.
The opening 551 enters into the cavity 520 at a location along first axis A that is between the closure element 530 in its first, for example initial, position, and the cavity opening 521 . In other words, the opening 551 is located axially between the first position of the closure element 530 and the cavity opening 521 when viewed along the first axis A. The axial position of the opening 551 is preferably such that the closure element 530 when being in its initial position does not overlap with the opening 551, and that the closure element 530 in its final position does also not overlap with the opening 551. However, partial overlap in one or both of these positions of the closure element 530 with the opening 551 is encompassed by the present disclosure.
As shown in Fig. 12, after the main drug container production, the container 300 is (pre- )assembled with the adapter 500 for the pharmacy or clinic filling scenario. This assembly can be packed as a single piece. The adapter 500 contains the closure 530 which is needed to close the system. The design of adapter 500 is like a syringe, but instead of a plunger in a syringe the closure element 530 in the adapter 500 is moved by the push rod 540 inside the cavity
520. A connection to the adapter cavity 520 by the entry port 550 allows the filling of the drug container 300.
Fig.12 shows a septum 555 which can be pierced with a cannula multiple time. The septum 555 is arranged in the entry port channel 552 as a closure of the entry port 550 at the end opposite to the entry port opening 551. Alternatively, it is also possible to have a Luer connection or both, other non-Luer connections, or other suitable connectors. For example, a cooperating connection may be provided for a closed-system transfer device (CSTD) or components thereof to avoid user exposure to a medication filled into the drug container using the apparatus.
Fig. 13 illustrates the use of the adapter 500 of the second embodiment of the present invention. The left-hand figure shows the (pre-)assembled adapter 500 and drug container 300. The next stage of use is shown in the right-hand figure. It illustrates how the septum 555 is pierced by the filling syringe, and the medicament is transferred via the cavity 520 and through the cavity opening 521 into the medicament container 300 (medicament flow highlighted by the two arrows). Once the medicament container 300 is filled, the syringe is is removed, as by withdrawal, unscrewing, etc. If needed, one or more further components can be inserted this way into the container 300. Thus, this process may be repeated any number of times if necessary. For instance, if a 50ml syringe is used with the apparatus, and a 100ml dose is desired in the medicament bag, the process described may be repeated twice. Likewise, two 50ml syringes could be each filled with a different medication (for instance, a biologic medication and normal saline) and each added to the bag in sequence.
Fig. 14 illustrates further steps of the use of the adapter 500 of the second embodiment of the present invention. Fig. 14 shows the stoppering and the removal of the adapter 500 from the drug container. When all drug components are in the drug container 300, the push rod 540 of the adapter 500 is pressed. First, the closure element 530 acts as a plunger and pushes all drug elements remaining in the cavity 520 into the drug container 300. The user may push with the thumb on the push rod 540 and concurrently holds the two wings 560 with index finger and middle finger to apply a force on the push rod 540 (see left-hand figure). At the end position (center figure) the closure element 530 is connected to the port, it for example snaps
in, and seals and closes the drug container 300. By further pressing the push rod 540 of the adapter (right-hand figure) until the push rod 540 contacts the housing 510, the connection between the closure element 530 and the adapter 500 releases and the adapter 500 can be removed from the drug container 300 and discarded. The closure element 530 is now arranged on the drug container 300. The right-hand figure shows that the adapter housing 510 is already lifted a certain distance from the drug container 300.
Figs. 15 to 17 show the container 300 according to an aspect of the present invention in more detail. The container 300 is adapted to accommodate the medicament bag 310. In the illustrated embodiment, the medicament bag 310 is flexible. The medicament bag 310 has an inner space to accommodate a volume of liquid. The container 300 comprises a container housing 320 for accommodating the flexible bag 310, and in the illustrated embodiment supporting the medicament bag 310. The container 300 also has an entry port (or outlet port, respectively) 343 for accommodating or receiving the port 330 of the medicament bag 310 for communication of the inner space of the medicament bag 310 with the exterior of the container 300. The inlet port 343 is formed as a through hole. The container 300 has a container housing case or container frame 322 and a container housing lid 321. When the lid 321 is connected to the case or frame 322, the inner space for the medicament bag 310 is provided. However, the lid 321 is a preferred element, the container 300 could accommodate the flexible bag 310 without being closed by lid 321. The container housing lid 321 and the container housing case 322 each have a perimeter wall 323, 324. The perimeter walls 323, 324 provide rigidity to the container housing 320.
The container 300 also has one or more container connecting elements 340. The connecting elements 340 are adapted to mate with corresponding connecting elements of a flexible bag filling adapter, such as the adapter 100,500 of the present disclosure. In the illustrated embodiment two connecting elements 340 are provided. These are preferably arranged one on each side of the inlet port 343.
Preferably, each container connecting element 340 comprises a locking feature 341. More preferably, the one or more container locking features 341 comprise a case locking feature 3411 and a lid locking feature 3412. In other words, when the container 300 has a lid and the
container300 is coupled to an adapter 100, 500, the adapter 100, 500 is coupled or connected to the container housing case 322 and the container housing lid 321. This allows for a coupling direction along the axis of the port 343. For example, the locking features 3411 and 3412 on the lid and on the case provide for a snap-on connection of the adapter on the container 300. Alternatively, the locking feature is provided only in the container housing case 322 and not in the container housing lid 321. With such a configuration the adapter 100, 500 can be coupled to the container 300 for example in a sliding movement perpendicular to the axis of the port 343.
In the preferred embodiment shown in Figs. 15 to 17, the container connecting element 340 is formed as a recess in the circumferential walls 323, 324 of the container housing case 322 and the container housing lid 321. The respective locking feature 341 is preferably formed as a ridge or ledge at the wall of the recess. The ridge or ledge can mate with a corresponding ledge on the adapter connecting element to releasably couple the two components together.
The adapter 100, 500, adapter housing 110, 510, and push rod 140, 540 may be constructed of one or more rigid plastic materials, such as polypropylene, polycarbonate, acrylonitrile butadiene styrene, polyamide, polystyrene, or combinations thereof. In some embodiments, portions of adapter housing 110, 510, and push rod 140, 540 may be over-molded on the side closest to the container 300 body with a soft, compliant material, such as thermoplastic elastomer or thermoplastic polyurethane, to improve comfort for a user of the device during filling of the container 300 or placement of the closure element 130,530.
The devices described herein can be used forthe treatment and/or prophylaxis of one or more of many different types of disorders.
Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn's disease and ulcerative colitis), hypercholesterolaemia and/or dyslipidemia, cardiovascular disease, diabetes (e.g. type 1 or 2 diabetes), psoriasis, psoriatic arthritis, spondyloarthritis, hidradenitis suppurativa, Sjogren's syndrome, migraine, cluster headache, multiple sclerosis, neuromyelitis optica spectrum disorder, anaemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anaemia, hereditary angioedema, systemic
lupus erythematosus, lupus nephritis, myasthenia gravis, Behcet's disease, hemophagocytic lymphohistiocytosis, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid eye disease, nasal polyps, transplant, acute hypoglycaemia, obesity, anaphylaxis, allergies, sickle cell disease, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, systemic infusion reactions, immunoglobulin E (IgE)-mediated hypersensitivity reactions, cytokine release syndrome, immune deficiencies (e.g., primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy), enzyme deficiencies (e.g., Pompe disease, Fabry disease, Gaucher disease), growth factor deficiencies, hormone deficiencies, coagulation disorders (e.g., hemophilia, von Willebrand disease, Factor V Leiden), and cancer.
Exemplary types of drugs that could be included in the delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-drug conjugates, neutralizing antibodies, reversal agents, radioligand therapies, radioisotopes and/or nuclear medicines, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, nucleotides, protein analogues, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies.
Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as human epidermal growth factor receptor 2 (HER-2) receptor modulators, interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-1 (GLP-1) modulators,
glucose-dependent insulinotropic polypeptide (G I P) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, Cl esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B-cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR) modulators, cluster of differentiation 79B (CD79B) modulators, tumor-associated calcium signal transducer 2 (Trop-2) modulators, cluster of differentiation 52 (CD52) modulators, B-cell maturation antigen (BCMA) modulators, enzyme modulators, platelet-derived growth factor receptor A (PDGFRA) modulators, cluster of differentiation 319 (CD319 or SLAMF7) modulators, programmed cell death protein 1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors/modulators, B- lymphocyte antigen cluster of differentiation 19 (CD19) inhibitors, B-lymphocyte antigen cluster of differentiation 20 (CD20) modulators, cluster of differentiation 3 (CD3) modulators, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) modulators, T cell immunoreceptor with Ig and ITIM domains (TIGIT) modulators, V-domain Ig suppressor of T cell activation (VISTA) modulators, indoleamine 2,3-dioxygenase (IDO or INDO) modulators, poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG) modulators, lymphocyte-activation gene 3 (LAGS; also known as cluster of differentiation 223 or CD223) antagonists, cluster of differentiation 276 (CD276 or B7-H3) antigen modulators, cluster of differentiation 47 (CD47) antagonists, cluster of differentiation 30 (CD30) modulators, cluster of differentiation 73 (CD73) modulators, cluster of differentiation 66 (CD66) modulators, cluster of differentiation wl37 (CDwl37) agonists, cluster of differentiation 158 (CD158) modulators, cluster of differentiation 27 (CD27) modulators, cluster of differentiation 58 (CD58) modulators, cluster of differentiation 80 (CD80) modulators, cluster of differentiation 33 (CD33) modulators, cluster of differentiation 159 (CD159 or NKG2) modulators, glucocorticoid-induced TNFR- related (GITR) protein modulators, Killer Ig-like receptor (KIR) modulators, growth arrestspecific protein 6 (GAS6)/AXL pathway modulators, A proliferation-inducing ligand (APRIL) receptor modulators, human leukocyte antigen (HLA) modulators, epidermal growth factor receptor (EGFR) modulators, B-lymphocyte cell adhesion molecule modulators, cluster of differentiation wl23 (CDwl23) modulators, Erbb2 tyrosine kinase receptor modulators, endoglin modulators, mucin modulators, mesothelin modulators, hepatitis A virus cellular
receptor 2 (HAVCR2) antagonists, cancer-testis antigen (CTA) modulators, tumor necrosis factor receptor superfamily, member 4 (TNFRSF4 or 0X40) modulators, adenosine receptor modulators, inducible T cell co-stimulator (ICOS) modulators, cluster of differentiation 40 (CD40) modulators, tumor-infiltrating lymphocytes (TIL) therapies, or T-cell receptor (TCR) therapies.
Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to: etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, erenumab, galcanezumab, fremanezumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-la, interferon beta-lb, peginterferon beta-la, sumatriptan, darbepoetin alfa, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crizanlizumab-tmca, certolizumab pegol, satralizumab, denosumab, romosozumab, benralizumab, emicizumab, tildrakizumab, ocrelizumab, ofatumumab, natalizumab, mepolizumab, risankizumab-rzaa, ixekizumab, and immune globulins.
Exemplary drugs that could be included in the delivery devices described herein may also include, but are not limited to, oncology treatments such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab- pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90- Yttrium-ibritumomab tiuxetan, isatuximab, mogamulizumab, moxetumomab pasudotox, obinutuzumab, ofatumumab, olaratumab, panitumumab, polatuzumab vedotin, ramucirumab, sacituzumab govitecan, tafasitamab, or margetuximab.
Exemplary drugs that could be included in the delivery devices described herein include "generic" or biosimilar equivalents of any of the foregoing, and the foregoing molecular names should not be construed as limiting to the "innovator" or "branded" version of each, as in the non-limiting example of innovator medicament adalimumab and biosimilars such as adalimumab-afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.
Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, those used for adjuvant or neoadjuvant chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid. Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g. hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, antiseptics, anticoagulants, fibrinolytics (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombolytics, or diluents such as sterile water for injection (SWFI), 0.9% Normal Saline, 0.45% normal saline, 5% dextrose in water, 5% dextrose in 0.45% normal saline, Lactated Ringer's solution, Heparin Lock Flush solution, 100 U/mL Heparin Lock Flush Solution, or 5000 U/mL Heparin Lock Flush Solution.
Pharmaceutical formulations including, but not limited to, any drug described herein are also contemplated for use in the delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier. Such formulations may include one or more other active ingredients (e.g., as a combination of one or more active drugs), or may be the only active ingredient present, and may also include separately administered or co-formulated dispersion enhancers (e.g. an animal-derived, human-derived, or recombinant hyaluronidase enzyme), concentration modifiers or enhancers, stabilizers, buffers, or other excipients.
Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH,
GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOXG, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MIN E, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CH P, GCVP, DHAX, CALGB 8811, HIDAC, MOpAD, 7 + 3, 5 +2, 7 + 4, MEC, CVP, RBAC500, DHA-Cis, DHA-Ca, DHA-Ox, RCVP, RCEPP, RCEOP, CMV, DDMVAC, GemFLP, ITP, VIDE, VDC, VAI, VDC-IE, MAP, PCV, FCR, FR, PCR, HDMP, OFAR, EMA/CO, EMA/EP, EP/EMA, TP/TE, BEP, TIP, VIP, TPEx, ABVD, BEACOPP, AVD, Mini-BEAM, IGEV, C- MOPP, GCD, GEMOX, CAV, DT-PACE, VTD-PACE, DCEP, ATG, VAC, VelP, OFF, GTX, CAV, AD, MAID, AIM, VAC-IE, ADOC, or PE.
Various modifications to the embodiments described are possible and will occur to those skilled in the art without departingfrom the invention which is defined by the following claims.
The invention is further defined by the following clauses.
1. Adapter (100, 500) for filling and subsequent closing of a pharmaceutical composition container (300), the adapter (100, 500) comprising: a housing (110, 510) having a first axis (A), the housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521) coupleable to a port of the container (300); a closure element (130, 530) arranged in the cavity (120, 520) and displaceable from a first position to a second position, in a direction along the first axis (A); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user in a direction along the first axis (A) for displacing the closure element (130, 530); the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520), at least part of the entry port opening (151, 551) being located axially between the first position of the closure element (130, 530) and the cavity opening (121, 521) when viewed along the first axis (A).
2. The adapter (100, 500) of clause 1, wherein the entry port (150, 550) has an entry port channel (152, 552), at least part of the length of which is perpendicular to or is inclined with respect to the first axis (A).
3. The adapter (100, 500) of clause 1 or 2, wherein the adaptor (100, 500) has two opposing sides along the first axis (A), one side being the side where the adapter (100, 500) is connectable to a port (330) of the container (300), the other, second side for being held and/or operated by a user.
4. The adapter (100, 500) of any one of the preceding clauses, wherein the push rod (140, 540) has a generally T-shape in cross-section along the first axis (A).
5. The adapter (100, 500) of any one of the preceding clauses, wherein the adapter (100, 500) further comprises a pierceable septum (555) in the entry port channel (152, 552).
6. The adapter (100, 500) of any one of the preceding clauses, wherein the entry port (150, 550) comprises one or more of a self-sealing elastomeric septum, needleless connector, female Luer connection, male Luer connection, Luer access valve, Luer activated device, or combinations thereof, at the end opposite to the cavity opening (151, 551).
7. The adapter (100, 500) of any one of the preceding clauses, wherein the entry port (150, 550) is configured to cooperate with at least one or more of a male Luer connector, female Luer connector, vial adapter, vial spike, IV tubing set spike, or combinations thereof.
8. The adapter (100, 500) of any one of the preceding clauses, wherein the entry port (150, 550) is configured to cooperate with at least one closed-system transfer device or component.
9. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130, 530) is adapted to seal the port (330) of the container (300).
10. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130) is configured to remove substantially all of a drug from the cavity (120).
11. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130) is configured to remove substantially all of a drug from the cavity (120) after filling and displacement of the closure element (130, 530).
12. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130, 530) is adapted to enter into a connection with the port (330) of the container (300) and to be released from the adapter (100, 500) upon removal of the adapter (100, 500) from the container (300).
13. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130) is a plunger for expelling fluid from the cavity (120).
14. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130, 530) is a substantially elastomeric material.
15. The adapter (100, 500) of any one of the preceding clauses, wherein the closure element (130, 530) is a blend of thermoplastic elastomer and an olefin polymer.
16. The adapter (100, 500) of any one of the preceding clauses, wherein the cavity (120, 520) is made from an olefin polymer.
17. The adapter (100, 500) of any one of the preceding clauses, wherein the adapter (100, 500) is configured such that one or more portions of the adapter (100, 500) or the housing (110, 510) are removed from the container (300) after filling.
18. The adapter (100, 500) of any one of the preceding clauses, wherein the adapter (100, 500) is configured such that one or more portions of the adapter (100, 500) or the housing (110, 510) are removed from the container (300) after filling and displacement of the closure element (130, 530).
19. The adapter (500) of any one of the preceding clauses, wherein the adapter housing (510) has a protruding structure (560) for being gripped by a user during use.
20. The adapter (500) of clause 19, wherein the adapter housing (510) is generally elongate along the direction of the first axis (A), preferably generally cylindrical.
21. The adapter (500) of clause 19 or 20, wherein the push rod (540) protrudes along the first axis (A) from the adapter housing (510) at the side for being held and/or operated by a user.
22. The adapter (100) of any one of clauses 1 to 18, wherein the push rod (140) protrudes along the first axis (A) from the adapter housing (110) at the side for being held and/or operated by a user.
23. The adapter (100) of clause 22, wherein the adapter housing (110) has one or more connecting elements (160) for connecting the adapter housing (110) with the container housing (320).
24. The adapter (100) of clause 23, wherein the one or more connecting elements (160) provide a releasable connection between the adapter housing (110) with the container housing (320).
25. The adapter (100) of clause 24, wherein the releasable connection is a snap connection or a screw connection.
26. The adapter (100) of clause 23, 24, or 25, wherein the adapter housing (110) has a second axis (B) perpendicular to the first axis (A), and wherein the adapter housing (110) has two opposite connecting elements (160) for connecting the adapter housing (100) with the container housing (320), opposite along the second axis (B).
27. The adapter (100) of clause 26, wherein the connecting elements (160) are flexible elements providing a releasable connection to the container housing (320).
28. The adapter (100) of clause 27, wherein each flexible element is at its one end integral with the adapter housing (110) and the opposite flexible end comprising a locking feature (161).
29. The adapter (100) of clause 28, wherein the locking feature (161) is a ledge extending in a direction perpendicular to the plane defined by first axis (A) and second axis (B) and projecting along second axis (B), or the locking feature is a groove extending in a direction perpendicular to the plane defined by first axis (A) and the second axis (B) and being recessed along second axis (B).
30. The adapter (100) of any one of clauses 13 to 29, wherein the push rod (140) is embedded in the adapter housing (110) such that the outermost end surface (141) is flush with a surface (111) of the adapter housing (110).
31. The adapter (100) of clause 30, wherein the adapter housing (110) has a stepped structure so that the push rod (140) is displaceable towards the container (300).
32. The adapter (100) of clause 31, wherein the stepped structure is generally a U-shaped structure.
33. The adapter (100) of clause any one of the preceding clauses, wherein the entry port (150) comprises a valve element (170) for connecting the entry port (150) with a syringe (400).
34. The adapter (100) of clause 33, wherein the syringe (400) is a needleless syringe.
35. Container (300) for a pharmaceutical composition having a separable and removable adapter (100, 500) for filling and subsequent closing of the container (300), the adapter (100, 500) as defined in any one of the preceding clauses, the container (300) further comprising:
a medicament bag (310), and a port (330) configured for being removably connected with the adapter (100).
36. Container (300) according to clause 35, wherein the medicament bag (310) is a flexible medicament bag, preferably a flat flexible bag.
37. Container (300) according to clause 36, wherein the container (300) further comprises a container housing (320) accommodating the medicament bag (310).
38. Container (300) according to clause 37, wherein the port (330) is part of the medicament bag (310) or part of the container housing (320).
39. Container (300) according to clause 37 or 38, wherein the container housing (320) comprises one or more container connecting elements (340) mating with the adapter connecting elements (160).
40. Container (300) according to clause 39, wherein each container connecting element (340) comprises a locking feature (341).
41. Container (300) according to clause 40, wherein the locking feature (341) is a corresponding groove or ledge.
42. Container (300) for a flexible bag (310) having an inner space to accommodate a volume of liquid, the container (300) comprising: a container housing (320) for accommodating the flexible bag (310); an outlet port (343) for communication of the inner space of the flexible bag (310) with the exterior of the container (300); and one or more container connecting elements (340) mating with connecting elements (160) of a flexible bag filling adapter (100).
43. Container (300) according to clause 42, wherein each container connecting element (340) comprises a locking feature (341).
44. Container (300) according to clause 42 or 43, wherein the container housing (300) has a container housing case (322) and a container housing lid (321).
45. Container (300) according to clause 44, wherein the one or more container locking feature (341) comprise a case locking feature (3411) and a lid locking feature (3412).
46. Container (300) according to any one of clauses 42 to 45, wherein the container connecting element (340) is formed as a recess in the circumferential walls (323, 324) of the container housing case (322) and the container housing lid (321).
47. Container (300) according to clause 46, wherein the locking feature (341) is formed as a ridge at the wall of the recess.
48. Container (300) according to any one of clauses 42 to 47, further comprising an adapter (100, 500) for filling and subsequent closing of the flexible bag (310) in the container (300).
49. Container according to clause 48, wherein the adapter (100, 500) comprises: a housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521) coupleable to a port of the container (300); a closure element (130, 530) arranged in the cavity (120, 520); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user; the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520).
50. Combination of an adapter (100, 500) for filling and subsequent closing of a pharmaceutical composition container (300) and a container frame (322), the adapter (100, 500) comprising: a housing (110, 510) having a first axis (A), the housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521); a closure element (130, 530) arranged in the cavity (120, 520) and displaceable from a first position to a second position, in a direction along the first axis (A); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user in a direction along the first axis (A) for displacing the closure element (130, 530); the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520), at least part of the entry port opening (151, 551) being located axially between the first position of the closure element (130, 530) and the cavity opening (121, 521) when viewed along the first axis; wherein the adapter housing (110) has one or more connecting elements (160) for connecting the adapter housing (110) with the container frame (322).
51. The adapter (100) of clause 50, wherein the one or more connecting elements (160) provide a releasable connection between the adapter housing (110) with the container frame (322).
52. The adapter (100) of clause 51, wherein the releasable connection is a snap connection or a screw connection.
Claims
1. Adapter (100, 500) for filling and subsequent closing of a pharmaceutical composition container (300), the adapter (100, 500) comprising: a housing (110, 510) having a first axis (A), the housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521) coupleable to a port of the container (300); a closure element (130, 530) arranged in the cavity (120, 520) and displaceable from a first position to a second position, in a direction along the first axis (A); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user in a direction a long the first axis (A) for displacing the closure element (130, 530); the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520), at least part of the entry port opening (151, 551) being located axially between the first position of the closure element (130, 530) and the cavity opening (121, 521) when viewed along the first axis (A).
2. The adapter (100, 500) of claim 1, wherein the entry port (150, 550) has an entry port channel (152, 552), at least part of the length of which is perpendicular to or is inclined with respect to the first axis (A).
3. The adapter (100, 500) of claim 1 or 2, wherein the adaptor (100, 500) has two opposing sides along the first axis (A), one side being the side where the adapter (100, 500) is connectable to a port (330) of the container (300), the other, second side for being held and/or operated by a user.
4. The adapter (100, 500) of any one of the preceding claims, wherein the closure element (130, 530) is adapted to seal the port (330) of the container (300).
5. The adapter (100, 500) of any one of the preceding claims, wherein the closure element (130, 530) is adapted to enter into a connection with the port (330) of the container (300) and to be released from the adapter (100, 500) upon removal of the adapter (100, 500) from the container (300).
6. The adapter (100, 500) of any one of the preceding claims, wherein the closure element (130) is a plunger for expelling fluid from the cavity (120).
7. The adapter (500) of any one of the preceding claims, wherein the adapter housing (510) has a protruding structure (560) for being gripped by a user during use.
8. The adapter (100) of any one of claims 1 to 6, wherein the push rod (140) protrudes along the first axis (A) from the adapter housing (110) at the side for being held and/or operated by a user.
9. The adapter (100) of claim 8, wherein the adapter housing (110) has one or more connecting elements (160) for connecting the adapter housing (110) with the container housing (320).
10. The adapter (100) of any one of claims 13 to 20, wherein the push rod (140) is embedded in the adapter housing (110) such that the outermost end surface (141) is flush with a surface (111) of the adapter housing (110).
11. Container (300) for a pharmaceutical composition having a separable and removable adapter (100, 500) for filling and subsequent closing of the container (300), the adapter (100, 500) as defined in any one of the preceding claims, the container (300) further comprising: a medicament bag (310), and a port (330) configured for being removably connected with the adapter (100).
12. Container (300) for a flexible bag (310) having an inner space to accommodate a volume of liquid, the container (300) comprising: a container housing (320) for accommodating the flexible bag (310); an outlet port (343) for communication of the inner space of the flexible bag (310) with the exterior of the container (300); and one or more container connecting elements (340) mating with connecting elements
13. Container (300) according to claim 12, further comprising an adapter (100, 500) for filling and subsequent closing of the flexible bag (310) in the container (300).
14. Container according to claim 13, wherein the adapter (100, 500) comprises: a housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521) coupleable to a port of the container (300); a closure element (130, 530) arranged in the cavity (120, 520); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user; the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520).
15. Combination of an adapter (100, 500) for filling and subsequent closing of a pharmaceutical composition container (300) and a container frame (322), the adapter (100, 500) comprising: a housing (110, 510) having a first axis (A), the housing (110, 510) having a cavity (120, 520) with a cavity opening (121, 521); a closure element (130, 530) arranged in the cavity (120, 520) and displaceable from a first position to a second position, in a direction along the first axis (A); a push rod (140, 540) being arranged at least partially outside the cavity (120, 520) and being movable by a user in a direction a long the first axis (A) for displacing the closure element (130, 530); the housing (110, 510) having an entry port (150, 550) with an entry port opening (151, 551) in communication with the cavity (120, 520), at least part of the entry port opening (151, 551) being located axially between the first position of the closure element (130, 530) and the cavity opening (121, 521) when viewed along the first axis; wherein the adapter housing (110) has one or more connecting elements (160) for connecting the adapter housing (110) with the container frame (322).
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263427141P | 2022-11-22 | 2022-11-22 | |
US63/427,141 | 2022-11-22 | ||
US202363455088P | 2023-03-28 | 2023-03-28 | |
US63/455,088 | 2023-03-28 | ||
EP23191707.1 | 2023-08-16 | ||
EP23191707 | 2023-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024110558A1 true WO2024110558A1 (en) | 2024-05-30 |
Family
ID=88863317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/082757 WO2024110558A1 (en) | 2022-11-22 | 2023-11-22 | Adapter for filling and subsequent closing of a pharmaceutical composition container, and container with adapter |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024110558A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722727A (en) * | 1984-07-18 | 1988-02-02 | Abbott Laboratories | Flexible container |
JPS63248604A (en) * | 1987-04-03 | 1988-10-14 | 凸版印刷株式会社 | Germless filling method of fluid into bag |
WO2008089948A2 (en) * | 2007-01-25 | 2008-07-31 | Fresenius Medical Care Deutschland Gmbh | Closure for filling and sealing receptacles containing medicinal fluids and method for filling a receptacle with a medicinal fluid and sealing the receptacle |
WO2021108024A1 (en) * | 2019-11-25 | 2021-06-03 | Deka Products Limited Partnership | System for producing and packaging fluid, sealing member dispenser, reservoir feeding apparatus, bag sealing apparatus, reservoir filling set, method for filling a reservoir or a bag, filling and sampling nozzle |
WO2023148320A1 (en) * | 2022-02-04 | 2023-08-10 | Fresenius Kabi Deutschland Gmbh | Infusion bag, and method for producing same |
-
2023
- 2023-11-22 WO PCT/EP2023/082757 patent/WO2024110558A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722727A (en) * | 1984-07-18 | 1988-02-02 | Abbott Laboratories | Flexible container |
JPS63248604A (en) * | 1987-04-03 | 1988-10-14 | 凸版印刷株式会社 | Germless filling method of fluid into bag |
WO2008089948A2 (en) * | 2007-01-25 | 2008-07-31 | Fresenius Medical Care Deutschland Gmbh | Closure for filling and sealing receptacles containing medicinal fluids and method for filling a receptacle with a medicinal fluid and sealing the receptacle |
US8763798B2 (en) | 2007-01-25 | 2014-07-01 | Fresenius Medical Care Deutschland Gmbh | Closure for filling and sealing receptacles containing medicinal fluids and method for filling a receptacle with a medicinal fluid and sealing the receptacle |
WO2021108024A1 (en) * | 2019-11-25 | 2021-06-03 | Deka Products Limited Partnership | System for producing and packaging fluid, sealing member dispenser, reservoir feeding apparatus, bag sealing apparatus, reservoir filling set, method for filling a reservoir or a bag, filling and sampling nozzle |
WO2023148320A1 (en) * | 2022-02-04 | 2023-08-10 | Fresenius Kabi Deutschland Gmbh | Infusion bag, and method for producing same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112118821B (en) | Tandem-able drug modules for combination drug delivery devices | |
WO2024110558A1 (en) | Adapter for filling and subsequent closing of a pharmaceutical composition container, and container with adapter | |
WO2024156433A1 (en) | Medicament delivery system | |
WO2024146775A1 (en) | Medicament delivery system and method therefor | |
WO2024217870A1 (en) | Medicament bag assembly | |
WO2024165491A1 (en) | Cartridge driver, medicament delivery device and method for operating a medicament delivery device | |
WO2024231105A1 (en) | Medicament delivery system and method therefor | |
WO2024194029A1 (en) | Medicament delivery device | |
WO2024146842A1 (en) | Medicament delivery device | |
WO2024184513A1 (en) | A subassembly of a medicament delivery device | |
WO2024188691A1 (en) | Medicament delivery device | |
WO2024047206A1 (en) | Support for a flexible bag containing liquid medication, flexible bag unit, and medication delivery device | |
KR20240113956A (en) | Subassembly for drug delivery device | |
WO2024052241A1 (en) | Short-range communicating infusion tubing sets and methods of use | |
WO2024146838A1 (en) | Medicament delivery device | |
WO2024156431A1 (en) | Medicament delivery device | |
WO2024146837A1 (en) | Medicament delivery device | |
WO2024156430A1 (en) | Medicament delivery device package assembly | |
WO2024126093A1 (en) | Safety injection device for delivering a drug | |
WO2024156432A1 (en) | Medicament delivery device | |
WO2024156427A1 (en) | Medicament delivery device | |
WO2024052236A2 (en) | A shielded flexible bag for delivering radioactive medicaments, a shielded medication delivery cassette for radioactive medicaments and a shielded tubing set for administration of radioactive medicaments | |
WO2024188693A1 (en) | Medicament delivery device | |
WO2024153406A1 (en) | A subassembly of a medicament delivery device | |
WO2024153448A1 (en) | Injection device for delivering a drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23809260 Country of ref document: EP Kind code of ref document: A1 |